Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Design and production of conjugate vaccines against S. Paratyphi A using an O-linked glycosylation system in vivo.

Sun P, Pan C, Zeng M, Liu B, Liang H, Wang D, Liu X, Wang B, Lyu Y, Wu J, Zhu L, Wang H.

NPJ Vaccines. 2018 Feb 5;3:4. doi: 10.1038/s41541-017-0037-1. eCollection 2018.

2.

O-Serotype Conversion in Salmonella Typhimurium Induces Protective Immune Responses against Invasive Non-Typhoidal Salmonella Infections.

Li P, Liu Q, Luo H, Liang K, Yi J, Luo Y, Hu Y, Han Y, Kong Q.

Front Immunol. 2017 Dec 4;8:1647. doi: 10.3389/fimmu.2017.01647. eCollection 2017.

3.

Analysis of substrate specificity of Trypanosoma brucei oligosaccharyltransferases (OSTs) by functional expression of domain-swapped chimeras in yeast.

Poljak K, Breitling J, Gauss R, Rugarabamu G, Pellanda M, Aebi M.

J Biol Chem. 2017 Dec 8;292(49):20342-20352. doi: 10.1074/jbc.M117.811133. Epub 2017 Oct 17.

PMID:
29042445
4.

A recombinant O-polysaccharide-protein conjugate approach to develop highly specific monoclonal antibodies to Shiga toxin-producing Escherichia coli O157 and O145 serogroups.

Castillo DS, Rey Serantes DA, Melli LJ, Ciocchini AE, Ugalde JE, Comerci DJ, Cassola A.

PLoS One. 2017 Oct 5;12(10):e0182452. doi: 10.1371/journal.pone.0182452. eCollection 2017.

5.

Co-administration of the Campylobacter jejuni N-glycan based vaccine with probiotics improves vaccine performance in broiler chickens.

Nothaft H, Perez-Muñoz ME, Gouveia GJ, Duar RM, Wanford JJ, Lango-Scholey L, Panagos CG, Srithayakumar V, Plastow GS, Coros C, Bayliss CD, Edison AS, Walter J, Szymanski CM.

Appl Environ Microbiol. 2017 Sep 22. pii: AEM.01523-17. doi: 10.1128/AEM.01523-17. [Epub ahead of print]

PMID:
28939610
6.

DC2 and KCP2 mediate the interaction between the oligosaccharyltransferase and the ER translocon.

Shrimal S, Cherepanova NA, Gilmore R.

J Cell Biol. 2017 Nov 6;216(11):3625-3638. doi: 10.1083/jcb.201702159. Epub 2017 Aug 31.

PMID:
28860277
7.

Sophisticated Cloning, Fermentation, and Purification Technologies for an Enhanced Therapeutic Protein Production: A Review.

Gupta SK, Shukla P.

Front Pharmacol. 2017 Jul 4;8:419. doi: 10.3389/fphar.2017.00419. eCollection 2017. Review.

8.

Synthetic Microbial Ecology: Engineering Habitats for Modular Consortia.

Ben Said S, Or D.

Front Microbiol. 2017 Jun 16;8:1125. doi: 10.3389/fmicb.2017.01125. eCollection 2017.

9.

Refined topology model of the STT3/Stt3 protein subunit of the oligosaccharyltransferase complex.

Lara P, Öjemalm K, Reithinger J, Holgado A, Maojun Y, Hammed A, Mattle D, Kim H, Nilsson I.

J Biol Chem. 2017 Jul 7;292(27):11349-11360. doi: 10.1074/jbc.M117.779421. Epub 2017 May 16.

PMID:
28512128
10.

Two conserved oligosaccharyltransferase catalytic subunits required for N-glycosylation exist in Spartina alterniflora.

Jiang L, Zhu X, Chen J, Yang D, Zhou C, Hong Z.

Bot Stud. 2015 Dec;56(1):31. doi: 10.1186/s40529-015-0111-9. Epub 2015 Nov 11.

11.

Direct expression of active human tissue inhibitors of metalloproteinases by periplasmic secretion in Escherichia coli.

Lee KB, Nam DH, Nuhn JAM, Wang J, Schneider IC, Ge X.

Microb Cell Fact. 2017 Apr 28;16(1):73. doi: 10.1186/s12934-017-0686-9.

12.

Structural basis of inhibition of lipid-linked oligosaccharide flippase PglK by a conformational nanobody.

Perez C, Köhler M, Janser D, Pardon E, Steyaert J, Zenobi R, Locher KP.

Sci Rep. 2017 Apr 19;7:46641. doi: 10.1038/srep46641.

13.

The N-linking glycosylation system from Actinobacillus pleuropneumoniae is required for adhesion and has potential use in glycoengineering.

Cuccui J, Terra VS, Bossé JT, Naegeli A, Abouelhadid S, Li Y, Lin CW, Vohra P, Tucker AW, Rycroft AN, Maskell DJ, Aebi M, Langford PR, Wren BW; BRaDP1T Consortium.

Open Biol. 2017 Jan;7(1). pii: 160212. doi: 10.1098/rsob.160212.

14.

Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules.

Legastelois I, Buffin S, Peubez I, Mignon C, Sodoyer R, Werle B.

Hum Vaccin Immunother. 2017 Apr 3;13(4):947-961. doi: 10.1080/21645515.2016.1260795. Epub 2016 Dec 1. Review.

15.

Bibliometric analysis of publications on Campylobacter: (2000-2015).

Sweileh WM, Al-Jabi SW, Sawalha AF, AbuTaha AS, Zyoud SH.

J Health Popul Nutr. 2016 Nov 29;35(1):39.

16.

Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer.

Greville G, McCann A, Rudd PM, Saldova R.

Epigenetics. 2016 Dec;11(12):845-857. Epub 2016 Sep 30. Review.

17.

High-throughput recombinant protein expression in Escherichia coli: current status and future perspectives.

Jia B, Jeon CO.

Open Biol. 2016 Aug;6(8). pii: 160196. doi: 10.1098/rsob.160196. Review.

18.

Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.

Riddle MS, Kaminski RW, Di Paolo C, Porter CK, Gutierrez RL, Clarkson KA, Weerts HE, Duplessis C, Castellano A, Alaimo C, Paolino K, Gormley R, Gambillara Fonck V.

Clin Vaccine Immunol. 2016 Dec 5;23(12):908-917. Print 2016 Dec.

19.

Bacterial N-Glycosylation Efficiency Is Dependent on the Structural Context of Target Sequons.

Silverman JM, Imperiali B.

J Biol Chem. 2016 Oct 14;291(42):22001-22010. Epub 2016 Aug 29.

20.

Emerging facets of prokaryotic glycosylation.

Schäffer C, Messner P.

FEMS Microbiol Rev. 2017 Jan;41(1):49-91. doi: 10.1093/femsre/fuw036. Epub 2016 Aug 26. Review.

Supplemental Content

Support Center